Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Liquidia Technologies ( (LQDA) ).
On June 17, 2025, Liquidia Corporation held its annual meeting of stockholders where key decisions were made, including the election of three Class I directors, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025, and the approval of executive compensation. The meeting saw participation from holders of 67,560,757 shares, constituting a quorum, and all proposals were passed with significant support.
The most recent analyst rating on (LQDA) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Liquidia Technologies stock, see the LQDA Stock Forecast page.
Spark’s Take on LQDA Stock
According to Spark, TipRanks’ AI Analyst, LQDA is a Neutral.
Liquidia’s overall stock score is primarily impacted by its financial struggles, with significant debt and ongoing losses being major concerns. However, the recent FDA approval and favorable legal outcomes for YUTREPIA offer hope for future growth. Technical indicators are neutral, and the lack of profitability affects valuation.
To see Spark’s full report on LQDA stock, click here.
More about Liquidia Technologies
Liquidia Corporation is a company based in Delaware that operates in the pharmaceutical industry, focusing on developing innovative therapies using its proprietary PRINT technology.
Average Trading Volume: 1,861,413
Technical Sentiment Signal: Buy
Current Market Cap: $1.2B
See more data about LQDA stock on TipRanks’ Stock Analysis page.